RiboMAX™ AOF RNA Production System
Supports Optimization of IVT Reactions Specific to Your DNA Template
- Scalable reaction conditions that reliably produce high-quality RNA
- Co-transcriptionally incorporates standard or modified nucleotides and cap analogs
- Animal-origin-free reagents suitable for RNA synthesis from research to production scale
Catalog Number:
Size
Catalog Number: P2000
Animal Origin-Free In Vitro Transcription for RNA Therapeutics
In vitro synthesis of RNA suitable for RNA therapeutic development and production requires reactions that are not only efficient and scalable but can be adapted to maximize yield and purity for each RNA target. Maximizing reaction performance while minimizing variability, from research and early development through commercial production, is critical to success.
The RiboMAX™ AOF RNA Production System is designed to meet these demands. It features animal-origin-free (AOF), cGMP-manufactured components for robust, scalable in vitro transcription (IVT) of RNA. The system includes a standard IVT protocol along with reaction optimization guidance, which gives you the flexibility to tailor reaction conditions to your RNA target, both maximizing yield and minimizing impurities (such as double-stranded RNA).
Same Manufacturing Quality,
Additional Testing If and When You Need It
Animal Origin-Free Production – Animal origin-free manufacturing processes and raw materials.
Contamination Testing – Reduces the risks associated with contaminants that can potentially impact yield and quality of in vitro transcribed product.
Quality Documentation – Certificate of Analysis, Certificate of Origin and TSE/BSE Statements available upon request.
cGMP Reagents for mRNA Manufacturing
Trusted Technology, Modern Modalities
For over 40 years, we have been a leading provider of in vitro transcription reagents supporting a variety of applications.
To better serve and support the needs of our customers in the rapidly growing arena of mRNA therapeutic development, we have upgraded the manufacturing and quality attributes of our trusted raw material reagents to ensure they meet the strict quality requirements for the manufacture of mRNA therapeutics.
Primary Manufacturer
As a primary manufacturer, we control all aspects of product manufacturing, from raw materials through finished product. With integrated logistics support and multiple global inventory locations, we effectively eliminate uncertainty to ensure consistent supply.
Consistent Yield Efficiency and Scalable RNA Production
RNA yield from RiboMAX™ IVT reactions is scalable up to at least 10ml. Yield per milliliter of IVT reactions (left) and total yield (right) are shown. Each replicate RiboMAX™ reaction is represented as an individual bar. RiboMAX™ IVT reactions were prepared according to the protocol. Reactions (100μl, 1ml, 5ml and 10ml) were prepared in duplicate with the T7 Linear Control DNA (Part# P141A) as template (100μg/ml of reaction). No-RNA Polymerase controls (100μl) also were prepared (0.1ml – NE). Transcription reactions were incubated at 37°C for 4 hours. After transcription, RiboMAX™ reactions were diluted 100X in Nuclease-Free Water and assayed using the Qubit™ RNA BR Assay (Invitrogen) with 10μl of sample.
Comparison of Large-Scale In Vitro Transcription Kits
Comparison of large-scale IVT kits. The RiboMAX™ Large Scale RNA Production System-T7, HiScribe™ T7 High Yield RNA Synthesis Kit and TranscriptAid™ T7 High Yield Transcription Kit were used to synthesize 1.8kb luciferase transcripts and 5kb run-off transcripts containing standard nucleotides (Std.), N1-methylpseudo-UTP (U) and N1-methylpseudo-UTP + 5-methyl-CTP (U+C). Transcripts were co-transcriptionally capped using CleanCap® Reagent AG (3’ OMe) according to the protocol. Left: Transcription products were diluted 1:100 in Nuclease-Free Water and analyzed using the RNA ScreenTape Assay. The resulting gel images are displayed for transcripts synthesized using each kit. Bands are scaled to the highest peak in each lane (scaled to sample). Right: Transcripts (1.8kb) were purified using a column-based RNA cleanup kit and quantified using the QuantiFluor® RNA System (Cat.# E3310). Resulting purified 1.8kb transcript concentrations and yields are displayed.
Protocols
Specifications
Catalog Number:
選択製品の構成品内容
| Item | Part # | Size | Concentration | Available Separately |
|---|---|---|---|---|
rATP |
B225A | 1 × 525μl | 100mM | |
rGTP |
B226A | 1 × 525μl | 100mM | |
rCTP |
B227A | 1 × 525μl | 100mM | |
rUTP |
B228A | 1 × 525μl | 100mM | |
Magnesium Acetate |
L123A | 1 × 1000μl | 1M | |
Magnesium Chloride |
L124A | 1 × 1000μl | 1M | |
|
DTT |
V125A | 1 × 1.125ml | 1M | |
Inorganic Pyrophosphatase, AOF |
M934A | 1 × 55μl | 2u/μl | |
RNasin® Plus Ribonuclease Inhibitor, AOF |
N373A | 1 × 250μl | 40u/μl | |
T7 RNA Polymerase, AOF |
P617A | 1 × 275μl | 400u/μl | |
T7 Linear Control DNA |
P141B | 1 × 50μl | 1mg/ml | |
10X Transcription Buffer (Magnesium-Free) |
P211A | 1 × 1000μl | ||
|
Nuclease-Free Water |
P119A | 2 × 1,250μl | View Product |
Resources
Related Products
類似製品
RiboMAX™ Large-Scale RNA Production Systems
in vitro または in vivo 翻訳のためにキャップあり（またはキャップなし）の RNA 転写物を合成
P1280, P1300
T7 RiboMAX™ Express Large-Scale RNA Production System
Designed for speed. Produces 5–8.5mg/ml RNA in 30 minutes.
P1320
T7 RNA Polymerase
T7 プロモーター配列に極めて高い特異性を示すDNA依存性RNAポリメラーゼ
P2075, P2077, P4074, P618X, P617X
Ribonucleotide Triphosphates (rNTPs)
rATP, rUTP, rCTP or rGTP を10mM と 100mM の2つの濃度より選択可能
P1132, P1142, P1152, P1162, E6011, E6021, E6031, E6041, BX139X
関連製品
pGEM®-T Easy Vector Systems
３種類のインサートの切り出しオプションが選べるPCRクローニングベクター
A1360, A1380
Lumit® dsRNA Detection Assay
サンプル中のdsRNAを定量するための、NanoBiT®ルシフェラーゼの断片相補に基づく新技術
W2041, W2042, W2010, W2040, CS355710, CS355712, CS355714, CS355716
QuantiFluor® RNA System
溶液中の微量RNAの蛍光定量
E3310
Rabbit Reticulocyte Lysate, Nuclease-Treated
mRNA 種の同定、タンパク質の特性化 などに使用できる ウサギ網状赤血球ライセートベースの in vitro 翻訳システム
L4960
